Holen Sie sich die Stockscreener-App
9.5435
5.82%
0.5235
Schlusskurs vom Vortag:
$9.02
Offen:
$8.98
24-Stunden-Volumen:
2.60M
Relative Volume:
0.49
Marktkapitalisierung:
$2.39B
Einnahmen:
$874.84M
Nettoeinkommen (Verlust:
$263.86M
KGV:
7.9324
EPS:
1.2031
Netto-Cashflow:
$327.41M
1W Leistung:
+1.01%
1M Leistung:
+12.56%
6M Leistung:
+35.97%
1J Leistung:
+39.75%
1-Tages-Spanne:
$8.95
$9.675
1-Wochen-Bereich:
$8.92
$9.687
52-Wochen-Spanne:
$6.00
$11.31
Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile
Firmenname
Biocryst Pharmaceuticals Inc
Sektor
Telefon
919-859-1302
Adresse
4505 EMPEROR BOULEVARD, DURHAM, NC
Compare BCRX vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCRX
Biocryst Pharmaceuticals Inc
|
9.545 | 2.26B | 874.84M | 263.86M | 327.41M | 1.2031 |
TAK
Takeda Pharmaceutical Co Adr
|
18.20 | 59.20B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
118.24 | 49.79B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.935 | 44.27B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.68 | 35.03B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
554.53 | 24.75B | 3.18B | 1.33B | 1.04B | 27.90 |
Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Fortgesetzt | Evercore ISI | Outperform |
| 2025-10-15 | Fortgesetzt | TD Cowen | Buy |
| 2025-10-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-02-25 | Eingeleitet | Wedbush | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-08-04 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-13 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-02-22 | Hochstufung | Needham | Hold → Buy |
| 2022-11-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-05 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-04-18 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-04-11 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-08-06 | Herabstufung | Jefferies | Buy → Hold |
| 2021-08-03 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Overweight |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-05-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-11-15 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-05-24 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-11-16 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-08-08 | Fortgesetzt | JP Morgan | Overweight |
| 2018-07-17 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-06-22 | Eingeleitet | Seaport Global Securities | Neutral |
| 2018-01-02 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2017-12-20 | Eingeleitet | Barclays | Equal Weight |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-09-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2017-09-06 | Hochstufung | Jefferies | Hold → Buy |
| 2017-02-16 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-08-12 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-08-04 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | FBR Capital | Outperform |
| 2016-02-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2016-02-09 | Herabstufung | Needham | Buy → Hold |
Alle ansehen
Biocryst Pharmaceuticals Inc Aktie (BCRX) Neueste Nachrichten
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6%Here's What Happened - MarketBeat
BioCryst names Sandeep Menon as chief R&D officer By Investing.com - Investing.com Canada
BioCryst Pharmaceuticals Appoints Dr. Sandeep M. Menon as Chief Research and Development Officer - Quiver Quantitative
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer - marketscreener.com
BioCryst taps AMVUTTRA, PAXLOVID veteran to lead R&D effort - Stock Titan
BioCryst (BCRX) rallies 7.10% on acquisition buzz - MSN
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Operating cash flow per share of BioCryst Pharmaceuticals, Inc. – DUS:BO1 - TradingView
BioCryst Pharmaceuticals, Inc. (BCRX) stock price, news, quote and history - Yahoo Finance Singapore
BioCryst stock jumps after hours on big pharma suitor buzz — retail sentiment hits 2026 peak - MSN
How The BioCryst Pharmaceuticals (BCRX) Narrative Is Shifting With Astria Deal And FY26 Targets - Yahoo Finance
BCRX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioCryst (BCRX) soars 13% on acquisition buzz - MSN
BioCryst Pharmaceuticals Inc (BO1.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
Technical Reactions to BCRX Trends in Macro Strategies - news.stocktradersdaily.com
12 new BioCryst hires receive stock awards tied to 157,300 shares - Stock Titan
Investors Purchase High Volume of Call Options on BioCryst Pharmaceuticals (NASDAQ:BCRX) - MarketBeat
BCRX Forecast, Price Target & Analyst Ratings | BIOCRYST PHARMACEUTICALS INC (NASDAQ:BCRX) - ChartMill
BioCryst Pharmaceuticals Stock: Navigating Biotech Innovation and Investor Opportunities in Rare Dis - AD HOC NEWS
Assenagon Asset Management S.A. Lowers Holdings in BioCryst Pharmaceuticals, Inc. $BCRX - marketbeat.com
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by JPMorgan Chase & Co. - MarketBeat
Rate Cut: Is BioCryst Pharmaceuticals Inc subject to activist investor interest2026 Momentum & Reliable Breakout Stock Forecasts - baoquankhu1.vn
BioCryst 2025 slides: path to $1B revenue, Navenibart expands portfolio - Investing.com Canada
Earnings call transcript: BioCryst Q4 2025 shows strong growth, stock dips - Investing.com Australia
Earnings call transcript: BioCryst Q4 2025 shows strong growth, stock dips By Investing.com - Investing.com South Africa
BioCryst targets $1B ORLADEYO peak and $700M cash by 2027 as leadership shifts and pipeline advances - MSN
Why Did BCRX Stock Surge Over 10% In After-Hours Trading Today? - Stocktwits
Vanguard amends Schedule 13G — BioCryst (BCRX) ownership shown as 0 - Stock Titan
Does BioCryst Pharmaceuticals (BCRX) Still Offer Value After Recent Share Price Strength? - Sahm
BioCryst Shares Remain Undervalued, RBC Says - marketscreener.com
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $13 - Moomoo
RBC Capital reiterates BioCryst stock rating on takeout potential - Investing.com
RBC Capital reiterates BioCryst stock rating on takeout potential By Investing.com - Investing.com Canada
BioCryst appoints Charlie Gayer to succeed Jon Stonehouse as CEO - MSN
Insider Sell: Theresa Heggie Sells 49,933 Shares of BioCryst Pha - GuruFocus
Major Insider Move at BioCryst Shakes Up Investor Buzz - TipRanks
Buybacks Report: Is BioCryst Pharmaceuticals Inc benefiting from interest rate changes2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Hereditary Angioedema Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Biocryst Pharmaceuticals Insider Sold Shares Worth $504,823, According to a Recent SEC Filing - MarketScreener
Option exercise and sale by BioCryst (BCRX) director Theresa Heggie - Stock Titan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpWhat's Next? - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Finanzdaten der Biocryst Pharmaceuticals Inc-Aktie (BCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocryst Pharmaceuticals Inc-Aktie (BCRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HEGGIE THERESA | Director |
Mar 20 '26 |
Sale |
10.11 |
49,933 |
504,823 |
65,352 |
1.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):